- Home
- XFOR vs IVCA Comparison
XFOR vs IVCA Comparison
Compare XFOR & IVCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- IVCA
- Stock Information
- Founded
- XFOR 2014
- IVCA 2021
- Country
- XFOR United States
- IVCA Cayman Islands
- Employees
- XFOR N/A
- IVCA N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- IVCA Blank Checks
- Sector
- XFOR Health Care
- IVCA Finance
- Exchange
- XFOR Nasdaq
- IVCA Nasdaq
- Market Cap
- XFOR 118.4M
- IVCA 95.3M
- IPO Year
- XFOR N/A
- IVCA 2022
- Fundamental
- Price
- XFOR $0.19
- IVCA $12.10
- Analyst Decision
- XFOR Strong Buy
- IVCA
- Analyst Count
- XFOR 3
- IVCA 0
- Target Price
- XFOR $2.83
- IVCA N/A
- AVG Volume (30 Days)
- XFOR 1.9M
- IVCA 1.1K
- Earning Date
- XFOR 05-06-2025
- IVCA 01-01-0001
- Dividend Yield
- XFOR N/A
- IVCA N/A
- EPS Growth
- XFOR N/A
- IVCA N/A
- EPS
- XFOR N/A
- IVCA 0.18
- Revenue
- XFOR $2,557,000.00
- IVCA N/A
- Revenue This Year
- XFOR $355.69
- IVCA N/A
- Revenue Next Year
- XFOR $140.28
- IVCA N/A
- P/E Ratio
- XFOR N/A
- IVCA $67.86
- Revenue Growth
- XFOR N/A
- IVCA N/A
- 52 Week Low
- XFOR $0.19
- IVCA $11.22
- 52 Week High
- XFOR $1.39
- IVCA $12.37
- Technical
- Relative Strength Index (RSI)
- XFOR 29.03
- IVCA 58.17
- Support Level
- XFOR $0.20
- IVCA $11.60
- Resistance Level
- XFOR $0.22
- IVCA $12.24
- Average True Range (ATR)
- XFOR 0.03
- IVCA 0.05
- MACD
- XFOR 0.00
- IVCA 0.01
- Stochastic Oscillator
- XFOR 4.84
- IVCA 78.13
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About IVCA Investcorp India Acquisition Corp.
Investcorp AI Acquisition Corp is a blank check company.